Recap: Eli Lilly Q4 Earnings

Shares of Eli Lilly LLY decreased 0.3% in pre-market trading after the company reported Q4 results.

Quarterly Results

Earnings per share rose 58.96% year over year to $2.75, which beat the estimate of $2.35.

Revenue of $7,440,000,000 higher by 21.69% from the same period last year, which beat the estimate of $7,290,000,000.

Guidance

The upcoming fiscal year's EPS expected to be between $7.75 and $8.40.

The upcoming fiscal year's revenue expected to be between $26,500,000,000 and $28,000,000,000.

Conference Call Details

Date: Jan 29, 2021

Time: 09:00 AM

ET Webcast URL: https://edge.media-server.com/mmc/p/ku6m85kq

Technicals

52-week high: $213.23

Company's 52-week low was at $117.06

Price action over last quarter: Up 59.55%

Company Profile

Eli Lilly is a drug company with a focus on neuroscience, endocrinology, oncology, and immunology. Lilly's key products include Alimta and Verzenio for cancer; Jardiance, Trulicity, Humalog, and Humulin for diabetes; and Taltz and Olumiant for immunology.